Zevra Therapeutics, Inc. Additional Paid in Capital, Common Stock
Zevra Therapeutics, Inc. (ZVRA) had Additional Paid in Capital, Common Stock of $606.26 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $606.26M.
- 2026-03-31: Additional Paid in Capital, Common Stock $602.75M.
- 2025-12-31: Additional Paid in Capital, Common Stock $588.46M.
- 2025-09-30: Additional Paid in Capital, Common Stock $580.78M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $606.26M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $602.75M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $588.46M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $580.78M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $564.32M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $560.47M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $555.30M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $550.41M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $479.36M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $476.06M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $472.66M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $418.14M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $405.13M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $402.79M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $436.27M 10-K · filed 2024-04-01 | $401.80M 10-K · filed 2023-03-07 |
| 2022-09-30 | $400.68M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $399.70M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $397.93M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $396.96M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $396.06M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $393.23M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $353.02M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $192.06M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $191.28M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $187.74M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $182.79M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $171.26M 10-K · filed 2021-03-12 | $171.25M 10-K · filed 2020-02-28 |
| 2019-09-30 | $169.05M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $161.19M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $158.64M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $154.62M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $120.66M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $117.39M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $111.26M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $107.21M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $106.06M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $104.90M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $103.73M 10-Q · filed 2017-05-22 | |
| 2016-12-31 | $102.64M 10-K · filed 2018-03-30 | |
| 2016-09-30 | $101.60M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $98.32M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $96.28M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $94.70M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $89.87M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $89.34M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $1.78M 10-Q · filed 2015-05-29 | |
| 2014-12-31 | $1.65M 10-K · filed 2016-03-16 | $1.65M 10-Q · filed 2015-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |